Table 1.
Respiratory virus diagnosis and RSV- and HMPV-positive rates in the GLIViRe centers
| Center | 1 PV | 2 UNI-MI | 3 POL-MI | 4 BZ | 5 TV | 6 BO | 7 AN | 8 RM |
|---|---|---|---|---|---|---|---|---|
| N. of samples tested | 1749 | 569 | 1849 | 1978 | 3267 | 921 | 1036 | 208 |
| Molecular method | In-house assay [16] | In-house assay [16] | Anyplex™ II RV16 | Allplex™ Respiratory Panel | Allplex™ Respiratory Panel | FilmArray™ | FTD21™ | In-house assay [12] |
| Inclusion criteria | Clinic (all ages) | ILI (all ages) | Clinic (all ages) | Clinic (all ages) | Clinic (all ages) | Clinic (all ages) | Clinic (all ages) | Clinic (0–3 y) |
| Outpatients tested | yes | yes | yes | yes | yes | no | yes | no |
| N. of RSV-positive samples (%) | 157 (9.0%) | 46 (8.1%) | 304 (16.4%) | 264 (13.3%) | 210 (6.4%) | 131 (14.2%) | 122 (11.8%) | 66 (31.7%) |
| N. of RSV-A-positive samples (%)a | 20 (43.5%) | 16 (42.1%) | 98 (41.7%) | 26 (9.9%) | 60 (28.8) | 22 (42.3%) | 33 (28.2%) | 8 (16.7%) |
| N. of RSV-B-positive samples (%)a | 26 (56.5%) | 22 (57.9%) | 137 (58.3%) | 236 (90.1%) | 148 (71.2%) | 30 (57.7%) | 84 (71.8) | 48 (83.3%) |
| RSV-positive patients’ median age years (range) | 44.7 (0.04–93.5) | 9.7 (0.41–86.1) | 0.93 (0.02–92.5) | 0.89 (0.03–98.2) | 64.3 (0.04–98.5) | 0.43 (0.04–14.8) | 0.85 (0.04–91.4) | 0.84 (0.05–1.77) |
| HMPV-positive samples | 21 (1.2%) | ND | 77 (4.2%) | 32 (1.6%) | 58 (1.8%) | 13 (1.4%) | 17 (1.6%) | 4 (1.9%) |
| HMPV positive patients’ median age days (range) | 17.8 (0.06–84.9) | ND | 3.3 (0.11–84.3) | 4.6 (0.15 –85.1) | 69.2 (0.11 –97.4) | 1.3 (0.12 –3.5) | 3.1 (0.16 –57.4) | 0.76 (0.26 –1.3) |
RSV respiratory syncytial virus, HMPV human metapneumovirus, ILI influenza-like illness, ND not done
athe subtype % is calculated on the RSV-positive samples in the which one subtype could be assigned